Glibenclamide - What dose? [3]

South African Medical Journal

Volumn 97, Issue 7, 2007, Pages 475-

  Rambiritch, V ^a   Pillai, G ^b   Maharaj, B ^a   Robertson, L I ^c  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Dot Shuttleworth Centre for Diabetes   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; SULFONYLUREA; ANTIDIABETIC AGENT;

CLINICAL PRACTICE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG USE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; LETTER; MEDICAL AUDIT; MEDICATION ERROR; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; PRESCRIPTION; RECOMMENDED DRUG DOSE; SOUTH AFRICA; DOSE RESPONSE; DRUG UTILIZATION; ECONOMICS;

DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG UTILIZATION; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; SOUTH AFRICA;

EID: 34447635540     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (6)

1. Heerdink ER, Erquhart J, Leufkens HG. Changes in prescribed drug doses after market introduction. Pharmacoepidemiol Drug Saf 2002; 11: 447-453.
2. Robertson L, Jackson L. Sulphonyureas (specifically glibenclamide) and their correct dosage (Letter). S Afr Med J 1989; 76: 286-289.
3. Groop LC, Groop P-H, Stenman S, et al. Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment. Diabetes Care 1987; 10: 671-678.
4. Wahlin-Boll E, Almer L-O, Melander A. Bioavailability, kinetics and effects of glipizide in type 2 diabetics. Clin Pharmacokinet 1982; 7: 363-372.
5. Naidoo P, Virendra R, Layla M. Effects of gliclazicle dose escalation on postprandial hyperglycemia in type 2 diabetes mellittus: A prospective, open-label, case-controlled, dose-escalation study. Current Therapeutic Research 2006; 67: 81-102.
6. Huizar JF, Gonzalez LA, Alderman J, Smith HS. Sulphonylureas attenuate electrocardiographic ST-segment elevation during an acute myocardial infarction in diabetes. J Am Coll Cardiol 2003; 42: 1017-1021.